Project Grant R41GM146522

Award Date 9/1/22
Completion Date 2/29/24
Dollars Obligated $520K
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
Fayetteville, AR 72701, USA
Similar Awards
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under CFDA 93.859 Biomedical Research and Research Training program provides $306,860 to Mixedlcmedia LLC, a small disadvantaged business, to develop and evaluate a prototype ultra-low flow liquid chromatography platform based on their proprietary porous layer open-tubular (PLOT) and monolithic nanocolumn technologies. The goal is to create a commercialization-ready LC system that enables deep proteomic...
This National Science Foundation (NSF) Project Grant award for $380,074, awarded on September 1, 2024, aims to develop a platform for instrument-free, easy-to-interpret quantitative analysis of molecular biomarkers. The project will produce a general methodology adaptable to a range of molecular targets, including potential new agents. The key products to be delivered include: A "yes/no" output for quantitative measurement, enabled through stoichiometry and negative cooperativity-based...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) provides $295,561 to Biosensing Instrument Inc. to develop a commercial prototype of their Plasmonic Scattering Microscopy (PSM) technology. The PSM system aims to enable high-throughput, label-free quantification of membrane protein binding kinetics on single cells in their native cellular microenvironment. This represents a...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" program (CFDA 93.286) supports the development of a compact, semiconductor-based Single-Molecule Assay (SIMOA) system for sensitive detection of low-abundance protein biomarkers. The $447,304 award will fund the integration of microfluidics, electronics, and sensing capabilities within a...
This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Dcan Biosciences LLC to develop an advanced microfluidic system for cancer diagnosis and monitoring. The system aims to isolate and assess circulating tumor cells (CTCs) and CTC clusters (CTCCs) from patient blood samples to enable highly sensitive and accurate liquid biopsies. Key objectives include designing a hybrid microfluidic device for...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) provides $349,566 to Biosensing Instrument Inc. to develop a Spotting-Free Nano-Oscillator Array (SFNOA) technology for high-throughput, label-free quantification of ligand binding kinetics to transmembrane proteins in their native states. The SFNOA technology integrates several innovative techniques, including virion-displayed transmembrane...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $350,000 to Electronic Biosciences, Inc. to develop and demonstrate a novel enzyme-based, single-molecule protein sequencing system. The innovative platform aims to leverage enzyme-driven processing and sequencing of individual proteins and peptides, combined with advanced bioinformatics, to achieve high accuracy and...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under CFDA 93.859 Biomedical Research and Research Training program provides funding of $258,586 to MSTM LLC to develop an advanced surface sampling and ionization technology for remote detection of molecular compositions. The goal is to demonstrate the feasibility and proof-of-concept of a "Surface Reader" device that can directly sample surfaces using a liquid meniscus or indirectly via laser...
This $275,000 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program supports the development of a label-free, high-resolution, high-throughput protein screening platform called Vibrational Spectroscopy with Metasurface Optics (VISMO). The technology aims to enable simultaneous, minute-scale measurement of millions of protein samples, which would dramatically improve the lengthy and costly cycles...
This $249,000 Project Grant awarded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), supports the development of a novel split enzyme diagnostic platform for rapid, sensitive detection of protein and small molecule biomarkers at the point of care. The key products and services to be delivered through this grant include: Incorporating binding domains...

MICROWAVE-ENHANCED MICROREACTOR FOR ULTRAFAST DETECTION OF PROTEIN BIOMARKERS - PROJECT SUMMARY IN DIAGNOSIS, RISK STRATIFICATION, AND MANAGEMENT OF LIFE-THREATENING DISEASES/CONDITIONS, EVERY MINUTE COUNTS AND UNAMBIGUOUS DETECTION OF MANY RELEVANT PROTEIN BIOMARKERS IS CRUCIAL. UNFORTUNATELY, THE WORKFLOW OF CURRENT UNAMBIGUOUS APPROACH-MASS SPECTROMETRY-IS BOTTLENECKED BY THE SAMPLE PREPARATION PROCESS. A MICROWAVE-ENHANCED, FLOW-THROUGH MICROREACTOR IS PROPOSED HERE FOR BOTH SELECTIVE CAPTURE AND DIGESTION OF PROTEINS TO ADDRESS THIS MAJOR LIMITATION. THE SPECIFIC AIMS OF THIS PHASE I STTR ARE TO CREATE A PROTOTYPE MICROREACTOR AND TO DEMONSTRATE A PROOF OF CONCEPT OF THE MICROREACTOR-ENABLED MASS SPECTROMETRY ANALYSIS OF PROTEIN BIOMARKERS. THE PROPOSED TECHNOLOGY AND PRODUCT WILL STREAMLINE THE WORKFLOW OF MASS SPECTROMETRY ANALYSIS OF PROTEINS, FREE END USERS FROM THE LABORIOUS AND TEDIOUS MULTIPLE SAMPLE PREPARATION STEPS, AND ALLOW NEAR REAL-TIME AND UNAMBIGUOUS DETECTION OF PROTEIN BIOMARKERS, AS WELL AS THERAPEUTICS, DRUG TARGETS, ETC.

Posted 8/31/22, 12:00 AM